Business Context and Reporting Period
This Form 8-K filing by Akebia Therapeutics, Inc. reports on the results of the Company's 2018 Annual Meeting of Stockholders held on June 14, 2018. The Company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes
No material financial changes are reported in this filing. The primary events are the election of directors and the ratification of the independent auditor.
Corporate Governance and Voting Results
Stockholders approved the following matters:
- Director Elections: Six directors were elected to the Board of Directors. Three Class I directors were elected to serve until the 2021 annual meeting, and three Class III directors were elected to serve until the 2020 annual meeting.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Voting Summary
| Proposal / Director | Votes For | Votes Withheld / Against | Broker Non-Votes / Abstentions |
|---|---|---|---|
| Michael D. Clayman | 31,620,317 | 6,056,200 | 7,718,696 |
| Duane Nash | 32,200,119 | 5,476,398 | 7,718,696 |
| Ronald C. Renaud, Jr. | 32,202,388 | 5,474,129 | 7,718,696 |
| John P. Butler | 32,521,696 | 5,154,821 | 7,718,696 |
| Muneer A. Satter | 32,194,988 | 5,481,529 | 7,718,696 |
| Michael S. Wyzga | 32,202,394 | 5,474,123 | 7,718,696 |
| Ratify Ernst & Young LLP | 45,142,512 | 240,739 | 11,962 |
Investor Verification Checklist
- Verify the tenure of the newly elected directors (Class I vs. Class III) to understand the Board's composition through 2021.
- Review the significant number of broker non-votes (7,718,696) for director elections to assess potential proxy voting dynamics.
- Confirm the appointment of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2018.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.